Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific T-cell engagers, antibody-drug conjugates, and radionuclide therapies.
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease and node-positive disease at surgery or inoperable disease at diagnosis. Dr. Abraham makes special note of rates of interstitial lung disease seen in the trial and methods of management.
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers.
